DGIdb - CHLORPROMAZINE Drug Record

CHLORPROMAZINE chembl:CHEMBL71 Approved

Alternate Names:

CHLORPROMAZINE TANNATE
LARGACTIL
MEGAPHEN
CHLORPROMAZINE HIBENZATE
SONAZINE
SKF-2601A
J2.794D
CHLORPROMAZINE PHENOLPHTHALINATE
NSC-167745
ELMARIN
CHLORPROMAZINE
THORAZINE
NSC-226514
3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)-N,N-DIMETHYL-1-PROPANAMINE
N-(3-DIMETHYLAMINOPROPYL)-3-CHLOROPHENOTHIAZINE
CPZ
LARGACTIL®
3-(2-CHLOROPHENOTHIAZIN-10-YL)-N,N-DIMETHYL-PROPAN-1-AMINE
CHLORPROMAZINE HCL
THORAZINE®
rxcui:2403
chemidplus:50-53-3
drugbank:00477
chembl:CHEMBL71
pubchem.compound:2726

Drug Info:

(2 More Sources)

Publications:

Roth et al., 1994, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors., J. Pharmacol. Exp. Ther.
Kusumi et al., 2000, Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain., J Neural Transm (Vienna)
Yamada et al., 1995, Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice., Biol. Pharm. Bull.
Xu et al., 2008, BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population., Pharmacogenet. Genomics
Roth et al., 1995, D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs., Psychopharmacology (Berl.)
Oades et al., 2000, Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy., Behav Pharmacol
Wu et al., 2006, Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients., Acta Pharmacol. Sin.
Seeman, 2010, Dopamine D2 receptors as treatment targets in schizophrenia., Clin Schizophr Relat Psychoses
Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Tay JK et al., 2007, Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia., Prog Neuropsychopharmacol Biol Psychiatry
Muralidharan G et al., 1996, Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine., Eur J Clin Pharmacol
Freedman et al., 1994, Expression and pharmacological characterization of the human D3 dopamine receptor., J. Pharmacol. Exp. Ther.
Monostory et al., 2004, Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors., Chem. Biol. Interact.
Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
Pomeranz et al., 1987, The effect of chlorpromazine on cholecystokinin induced gallbladder contraction., Proc. West. Pharmacol. Soc.
Giardino et al., 1990, DA2/NT receptor balance in the mesostriatal and mesolimbocortical systems after chronic treatment with typical and atypical neuroleptic drugs., Brain Res.
Wang et al., 2008, Antipsychotic drugs inhibit the function of breast cancer resistance protein., Basic Clin. Pharmacol. Toxicol.
Wang et al., 2006, Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein., Psychopharmacology (Berl.)
Liu et al., 2003, Calmodulin is involved in heat shock signal transduction in wheat., Plant Physiol.

CHLORPROMAZINE CCK

Interaction Score: 2.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3628280

Sources:
NCI
CHLORPROMAZINE EPM2A

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27092952

Sources:
PharmGKB
CHLORPROMAZINE NTS

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1980851

Sources:
NCI
CHLORPROMAZINE DRD2

Interaction Score: 0.36

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
11103886 16867246 20643630 15694263 8524985 11873706 11752352 7908055 9918131 9858029 28673279 20194480 18926547 17105675 16513877 15830237 11505224

Sources:
ChemblInteractions PharmGKB TTD
CHLORPROMAZINE CYP2E1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15135088

Sources:
NCI
CHLORPROMAZINE HTR7

Interaction Score: 0.26

Interaction Types & Directionality:

binder

antagonist (inhibitory)

Interaction Info:

PMIDs:
7908055

Sources:
NCI
CHLORPROMAZINE HSPA4

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12857801

Sources:
NCI
CHLORPROMAZINE DRD4

Interaction Score: 0.14

Interaction Types & Directionality:

binder

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction D2-like dopamine receptor antagonist

PMIDs:
8524985

Sources:
ChemblInteractions
CHLORPROMAZINE HTR2A

Interaction Score: 0.12

Interaction Types & Directionality:

binder

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist

Direct Interaction yes

PMIDs:
7908055 10821438 8593484

Sources:
ChemblInteractions
CHLORPROMAZINE ABCG2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18834354

Sources:
NCI
CHLORPROMAZINE BDNF

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18408624

Sources:
NCI
CHLORPROMAZINE DRD3

Interaction Score: 0.09

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
8301582

Sources:
ChemblInteractions
CHLORPROMAZINE THPO

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHLORPROMAZINE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16810505

Sources:
NCI PharmGKB
CHLORPROMAZINE NR1I2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CHLORPROMAZINE CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17611010

Sources:
DTC PharmGKB
CHLORPROMAZINE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8739822

Sources:
DTC PharmGKB
CHLORPROMAZINE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CHLORPROMAZINE TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHLORPROMAZINE IDH1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHLORPROMAZINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

NCI: CHLORPROMAZINE

Version: 14-September-2017

Alternate Names:

C367 NCI drug code

Drug Info:

Publications:

Xu et al., 2008, BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population., Pharmacogenet. Genomics

Monostory et al., 2004, Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors., Chem. Biol. Interact.

Wang et al., 2008, Antipsychotic drugs inhibit the function of breast cancer resistance protein., Basic Clin. Pharmacol. Toxicol.

DTC: CHLORPROMAZINE
- Version: 02-September-2020
Alternate Names:

CHEMBL71 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: chlorpromazine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.

Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry

Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics

TTD: Chlorpromazine
- Version: 2020.06.01
Alternate Names:

D01ZII TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL71
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL71
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	D2-like dopamine receptor antagonist
Direct Interaction	yes

Mechanism of Interaction	Serotonin 2a (5-HT2a) receptor antagonist
Direct Interaction	yes

binder
antagonist (inhibitory)

binder
antagonist (inhibitory)

binder
antagonist (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

CHLORPROMAZINE Drug Record

CHLORPROMAZINE chembl:CHEMBL71 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3628280

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27092952

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1980851

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction D2-like dopamine receptor antagonist Direct Interaction yes

PMIDs: 11103886 16867246 20643630 15694263 8524985 11873706 11752352 7908055 9918131 9858029 28673279 20194480 18926547 17105675 16513877 15830237 11505224

Sources: ChemblInteractions PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15135088

Sources: NCI

Interaction Types & Directionality: binder antagonist (inhibitory)

Interaction Info:

PMIDs: 7908055

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12857801

Sources: NCI

Interaction Types & Directionality: binder antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction D2-like dopamine receptor antagonist

PMIDs: 8524985

Sources: ChemblInteractions

Interaction Types & Directionality: binder antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist Direct Interaction yes

PMIDs: 7908055 10821438 8593484

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18834354

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18408624

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction D2-like dopamine receptor antagonist Direct Interaction yes

PMIDs: 8301582

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16810505

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17611010

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8739822

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
3628280

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27092952

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
1980851

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
11103886 16867246 20643630 15694263 8524985 11873706 11752352 7908055 9918131 9858029 28673279 20194480 18926547 17105675 16513877 15830237 11505224

Sources:
ChemblInteractions PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
15135088

Sources:
NCI

Interaction Types & Directionality:

binder

antagonist (inhibitory)

PMIDs:
7908055

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12857801

Sources:
NCI

Interaction Types & Directionality:

binder

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction D2-like dopamine receptor antagonist

PMIDs:
8524985

Sources:
ChemblInteractions

Interaction Types & Directionality:

binder

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist

Direct Interaction yes

PMIDs:
7908055 10821438 8593484

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
18834354

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18408624

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

PMIDs:
8301582

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
16810505

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17611010

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
8739822

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

C367 NCI drug code

Alternate Names:

CHEMBL71 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D01ZII TTD Drug ID